TEL AVIV, Israel — August 21, 2025 — Leads & Copy — Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab) announced that CEO Dr. Adi Mor will present at the H.C. Wainwright 27th Annual Global Investment Conference. The prerecorded presentation will be available via webcast starting September 5, 2025, at 7:00 am ET. Chemomab management will also host investor meetings during the conference on September 8 and 9, 2025.
The presentation can be accessed at: https://journey.ct.events/view/ac2a207f-54a8-4812-9d90-025b238d0eba
Chemomab is a clinical stage biotechnology company that develops therapeutics for fibro-inflammatory diseases. Chemomab developed nebokitug (CM-101), a monoclonal antibody that neutralizes CCL24. Nebokitug has demonstrated a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Based on data from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC), the company is preparing for potential initiation of a nebokitug Phase 3 trial in patients with PSC. Nebokitug has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC.
Contacts:
Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations,
Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com
Source: Chemomab Therapeutics Ltd.
